NCT02658487 2025-04-15
VITAL
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
Clinical Trials
13 trialsNCT02416388 2024-08-07
BIG-1
University Hospital, Angers
Phase 2/3 Recruiting
NCT01893320 2022-02-09
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03338348 2020-10-28
Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
University of Ulm
Phase 2 Completed
NCT02272478 2020-01-23
AML18
Cardiff University
Phase 2/3 Unknown
NCT00252382 2018-09-24
Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC
Sunesis Pharmaceuticals
Phase 2 Completed
NCT01191801 2018-08-22
VALOR
Sunesis Pharmaceuticals
Phase 3 Completed
NCT00298896 2018-07-26
Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
Sunesis Pharmaceuticals
Phase 2 Completed
NCT00541866 2018-01-09
Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans
Sunesis Pharmaceuticals
Phase 1/2 Completed
NCT02485353 2017-09-20
Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML
Indiana University
Phase NA Terminated
NCT00607997 2017-06-28
Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
Sunesis Pharmaceuticals
Phase 2 Completed
NCT00091585 2007-05-10
Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.
Sunesis Pharmaceuticals
Phase 1 Completed
NCT00094159 2007-05-10
Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors
Sunesis Pharmaceuticals
Phase 1 Completed